Showing results (341-350 of 402) with videos related to

Sort By:
Pageof 41
Plos Biology|July 3, 2018
Strength in numbers: Collaborative science for new experimental model systemsRoss F Waller, Phillip A Cleves, Maria Rubio-Brotons, et al.
Journal of Neurosurgery|July 19, 2014
A novel, reproducible, and objective method for volumetric magnetic resonance imaging assessment of enhancing glioblastomaCharles W Kanaly, Ankit I Mehta, Dale Ding, et al.
Biorxiv : the Preprint Server for Biology|September 26, 2025
Gene-sized DNA insertion at genomic safe harbors in human cells using a site-directed transposaseJames E Short, Lisa Sharek, Joshua F Meckler, et al.
Nucleic Acids Research|December 8, 2025
Gene-sized DNA insertion at genomic safe harbors in human cells using a site-directed transposaseJames E Short, Lisa Sharek, Joshua F Meckler, et al.
Leukemia|August 4, 2012
Gab2 signaling in chronic myeloid leukemia cells confers resistance to multiple Bcr-Abl inhibitorsF U Wöhrle, S Halbach, K Aumann, et al.
Therapeutic Advances in Medical Oncology|June 9, 2022
Clinical predictors of survival in patients with relapsed/refractory small-cell lung cancer treated with checkpoint inhibitors: a German multicentric real-world analysisJan A Stratmann, Radha Timalsina, Akin Atmaca, et al.
Frontiers in Oncology|September 9, 2020
Immunohistochemistry and Radiomic Features for Survival Prediction in Small Cell Lung CancerEleni Gkika, Matthias Benndorf, Benedict Oerther, et al.
Therapeutic Advances in Medical Oncology|November 25, 2021
Phase III double-blind study comparing the efficacy and safety of proposed biosimilar MYL-1402O and reference bevacizumab in stage IV non-small-cell lung cancerMark A Socinski, Cornelius F Waller, Tazeen Idris, et al.
European Journal of Drug Metabolism and Pharmacokinetics|October 4, 2023
Population Pharmacokinetics of MYL-1402O, a Proposed Biosimilar to Bevacizumab and Reference Product (Avastin®) in Patients with Non-squamous Non-small Cell Lung CancerJoel S Owen, Russell J Rackley, Matthew A Hummel, et al.
Clinical Lung Cancer|July 22, 2017
Symptom and Quality of Life Improvement in LUX-Lung 8, an Open-Label Phase III Study of Second-Line Afatinib Versus Erlotinib in Patients With Advanced Squamous Cell Carcinoma of the Lung After First-Line Platinum-Based ChemotherapyEnriqueta Felip, Vera Hirsh, Sanjay Popat, et al.
Pageof 41